Nachrichten zur Hims & Hers Health Inc. Aktie

Hims & Hers Health (HIMS) is back in the spotlight after its Q4 2025 earnings per share beat, which contrasted…

Hims & Hers Health (NYSE:HIMS) is facing a patent infringement lawsuit from Novo Nordisk over its compounded weight loss drugs.…

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.…

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.…

Key PointsHims & Hers offers direct-to-consumer healthcare in a digitally native manner.…

In late February 2026, Hims & Hers Health reported fourth-quarter 2025 results showing higher sales year on year but slightly…

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026…

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82.…

When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes…

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.…

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.…

Key PointsHims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4.…

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers…

Hims & Hers Health (HIMS) has capped FY 2025 with fourth quarter revenue of US$617.8 million and basic EPS of…

Hims & Hers executives struck a confident tone about the companys growth prospects on Monday as it launches new specialties…

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Lets…

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here…

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Morgan Stanley:Der Analyst von Morgan Stanley, Craig Hettenbach, stuft die Aktie von…

Frankfurt (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von XTB:Jens Klatt, Marktanalyst bei XTB, nimmt die Aktie von Hims & Hers (ISIN:…

Novo Nordisk filed a lawsuit against Hims & Hers Health (NYSE:HIMS) over alleged patent infringement tied to compounded weight loss…

Hims & Hers Health, Inc. (($HIMS)) has held its Q4 earnings call. Read on for the main highlights of the…

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Lets…

Hims & Hers Health remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on…

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global upside.…

Hims & Hers Health (NYSE:HIMS) launched a compounded GLP-1 weight-loss medication and withdrew it shortly after following FDA scrutiny.Novo Nordisk…

After reporting earnings yesterday, shares of Hims & Hers Health have fallen not because of fundamentals but rather guidance.…

Hims & Hers Healths revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Click…

Hims & Hers stock drops after Q4 revenue miss. Outlook trails estimates despite profit beat and strong subscriber growth.…

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results…

These are the stocks posting the largest moves in early trading.…

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft…